News
Featured News
Flexibility, creativity, and dedication to make better therapeutics are at the heart of what we do. Read more on recent updates and highlights around our contract drug manufacturing activities.
BIOVECTRA and Revolution Biomanufacturing Partner to Deliver Integrated mRNA Design and GMP Production Services — Partnership Combines Sequence Design Expertise with End-to-End GMP Manufacturing to Streamline mRNA Development and Scale-up
November 6, 2025
BIOVECTRA and Revolution Biomanufacturing Partner to Deliver Integrated mRNA Design and GMP Production Services — Partnership Combines Sequence Design Expertise with End-to-End GMP Manufacturing to Streamline mRNA Development and Scale-up
CHARLOTTETOWN, PEI and WORCESTER, MA – November 6, 2025 – BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that […]
BIOVECTRA is Honoured With 2025 CDMO Leadership Award, Biologics — Industry Recognizes BIOVECTRA’s Excellence in Microbial Fermentation, Recombinant Protein Production, and Aseptic Fill-Finish Capabilities.
CHARLOTTETOWN, Prince Edward Island – BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex […]
Agilent Completes Acquisition of BIOVECTRA
Pharmaceutical customers will benefit from a broader set of specialized CDMO capabilities SANTA CLARA, California, September 20, 2024 – Agilent Technologies Inc. (NYSE: A) […]
Agilent Technologies to Acquire BIOVECTRA Inc., Creating New Synergistic Opportunities to Improve Patient Care
CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of […]
BIOVECTRA partners on Canadian solution to establish a domestic supply chain for immunotherapies
BIOVECTRA is pleased to be part of a Canadian solution with our NGEN partners CCRM, Precision Nanosytems (Cytiva), Northern RNA, and OmniaBio to establish […]
BIOVECTRA Launches Specialized Capabilities in mRNA Drug Product Development and Biomanufacturing
CHARLOTTETOWN, PRINCE EDWARD ISLAND, November 17th, 2023 – Today BIOVECTRA celebrates the completion of its $90 million plus biologics expansion at the company’s new state-of-the-art Biomanufacturing […]
